HIV 广谱中和抗体的最新进展。
Recent progress in broadly neutralizing antibodies to HIV.
机构信息
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA, USA.
IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, CA, USA.
出版信息
Nat Immunol. 2018 Nov;19(11):1179-1188. doi: 10.1038/s41590-018-0235-7. Epub 2018 Oct 17.
Abstract
In this Review, we highlight some recent developments in the discovery and application of broadly neutralizing antibodies (bnAbs) to human immunodeficiency virus (HIV); i.e., antibodies able to neutralize diverse isolates of HIV. We consider the characterization of novel bnAbs, recent data on the effects of bnAbs in vivo in humans and animal models, and the importance of both kinds of data for the application of Abs to prophylaxis and therapy and to guide vaccine design. We seek to place newly discovered bnAbs in the context of existing bnAbs, and we explore the various characteristics of the antibodies that are most desirable for different applications.
摘要
在这篇综述中，我们强调了人类免疫缺陷病毒（HIV）中广泛中和抗体（bnAbs）的发现和应用的一些最新进展，即能够中和 HIV 多种分离株的抗体。我们考虑了新型 bnAbs 的特性、最近 bnAbs 在人类和动物模型体内的作用数据，以及这两种数据对于 Abs 在预防和治疗中的应用以及指导疫苗设计的重要性。我们试图将新发现的 bnAbs 置于现有的 bnAbs 背景下，并探讨对于不同应用最理想的抗体的各种特性。
相似文献
1
Recent progress in broadly neutralizing antibodies to HIV.
Nat Immunol. 2018 Nov;19(11):1179-1188. doi: 10.1038/s41590-018-0235-7. Epub 2018 Oct 17.
2
Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design.
PLoS Pathog. 2016 Aug 25;12(8):e1005815. doi: 10.1371/journal.ppat.1005815. eCollection 2016 Aug.
3
Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
AIDS Res Ther. 2017 Sep 12;14(1):50. doi: 10.1186/s12981-017-0178-3.
4
Broadly neutralizing antibodies and vaccine design against HIV-1 infection.
Front Med. 2020 Feb;14(1):30-42. doi: 10.1007/s11684-019-0721-9. Epub 2019 Dec 19.
5
Development of broadly neutralizing antibodies in HIV-1 infected elite neutralizers.
Retrovirology. 2018 Sep 5;15(1):61. doi: 10.1186/s12977-018-0443-0.
6
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development.
Curr Opin HIV AIDS. 2023 Nov 1;18(6):300-308. doi: 10.1097/COH.0000000000000820. Epub 2023 Sep 25.
7
Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.
J Virol. 2014 Mar;88(5):2645-57. doi: 10.1128/JVI.03228-13. Epub 2013 Dec 18.
8
How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.
Curr Opin HIV AIDS. 2017 May;12(3):229-240. doi: 10.1097/COH.0000000000000360.
9
Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
J Virol. 2017 Apr 13;91(9). doi: 10.1128/JVI.02425-16. Print 2017 May 1.
10
Broadly Neutralizing Antibodies Against HIV: New Insights to Inform Vaccine Design.
Annu Rev Med. 2016;67:185-200. doi: 10.1146/annurev-med-091014-090749. Epub 2015 Nov 9.
引用本文的文献
1
A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.
Nat Commun. 2025 Aug 15;16(1):7580. doi: 10.1038/s41467-025-63101-1.
2
Selection of Cyclized, Glycosylated Peptide Antigens That Tightly Bind HIV High Mannose Patch Antibodies.
ACS Cent Sci. 2025 Jun 12;11(7):1122-1134. doi: 10.1021/acscentsci.5c00539. eCollection 2025 Jul 23.
3
Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.
AIDS Res Treat. 2025 Jul 4;2025:6829446. doi: 10.1155/arat/6829446. eCollection 2025.
4
Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination.
Viruses. 2025 May 26;17(6):756. doi: 10.3390/v17060756.
5
A potent and broad CD4 binding site neutralizing antibody with strong ADCC activity from a Chinese HIV-1 elite neutralizer.
Cell Discov. 2025 Jun 10;11(1):55. doi: 10.1038/s41421-025-00808-x.
6
A machine learning framework to identify complex physicochemical features of B cell epitopes.
Res Sq. 2025 Apr 18:rs.3.rs-6255613. doi: 10.21203/rs.3.rs-6255613/v1.
7
Making Universal Vaccines and Antibodies Through Glycoengineering.
Methods Mol Biol. 2025;2926:35-50. doi: 10.1007/978-1-0716-4542-0_3.
8
Quantifying prevalence and risk factors of HIV multiple infection in Uganda from population-based deep-sequence data.
PLoS Pathog. 2025 Apr 22;21(4):e1013065. doi: 10.1371/journal.ppat.1013065. eCollection 2025 Apr.
9
Multilayered HIV-1 resistance in HSPCs through CCR5 Knockout and B cell secretion of HIV-inhibiting antibodies.
Nat Commun. 2025 Apr 1;16(1):3103. doi: 10.1038/s41467-025-58371-8.
10
Identification of a mimotope of a complex gp41 human immunodeficiency virus epitope related to a non-structural protein of previously implicated in Kawasaki disease.
Microbiol Spectr. 2025 Mar 31;13(5):e0191124. doi: 10.1128/spectrum.01911-24.
本文引用的文献
1
Differential processing of HIV envelope glycans on the virus and soluble recombinant trimer.
Nat Commun. 2018 Sep 12;9(1):3693. doi: 10.1038/s41467-018-06121-4.
2
Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.
Cell Rep. 2018 Aug 21;24(8):1958-1966.e5. doi: 10.1016/j.celrep.2018.07.080.
3
Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Retrovirology. 2018 Jul 28;15(1):52. doi: 10.1186/s12977-018-0433-2.
4
Complete functional mapping of infection- and vaccine-elicited antibodies against the fusion peptide of HIV.
PLoS Pathog. 2018 Jul 5;14(7):e1007159. doi: 10.1371/journal.ppat.1007159. eCollection 2018 Jul.
5
The human naive B cell repertoire contains distinct subclasses for a germline-targeting HIV-1 vaccine immunogen.
Sci Transl Med. 2018 Jul 4;10(448). doi: 10.1126/scitranslmed.aat0381.
6
HIV-1 Subtype C-Infected Children with Exceptional Neutralization Breadth Exhibit Polyclonal Responses Targeting Known Epitopes.
J Virol. 2018 Aug 16;92(17). doi: 10.1128/JVI.00878-18. Print 2018 Sep 1.
7
Co-evolution of HIV Envelope and Apex-Targeting Neutralizing Antibody Lineage Provides Benchmarks for Vaccine Design.
Cell Rep. 2018 Jun 12;23(11):3249-3261. doi: 10.1016/j.celrep.2018.05.046.
8
Epitope-based vaccine design yields fusion peptide-directed antibodies that neutralize diverse strains of HIV-1.
Nat Med. 2018 Jun;24(6):857-867. doi: 10.1038/s41591-018-0042-6. Epub 2018 Jun 4.
9
HIV-1 Vaccines Based on Antibody Identification, B Cell Ontogeny, and Epitope Structure.
Immunity. 2018 May 15;48(5):855-871. doi: 10.1016/j.immuni.2018.04.029.
10
Identification of Near-Pan-neutralizing Antibodies against HIV-1 by Deconvolution of Plasma Humoral Responses.
Cell. 2018 Jun 14;173(7):1783-1795.e14. doi: 10.1016/j.cell.2018.03.061. Epub 2018 May 3.
Zotero 插件